Clinical Report: Incidence of Sensorineural Hearing Loss in HNC Patients

Overview

This systematic review and meta-analysis evaluates the incidence of sensorineural hearing loss (SNHL) in head and neck cancer patients undergoing chemoradiotherapy compared to those receiving radiotherapy alone. The findings indicate a significantly higher prevalence of SNHL in patients treated with chemoradiotherapy, particularly with cisplatin-based regimens.

Background

Head and neck cancer (HNC) is a prevalent cancer type with significant morbidity and mortality rates. The treatment often involves chemoradiotherapy, which, while effective, carries a risk of various side effects, including hearing loss. Understanding the incidence of SNHL in these patients is crucial for optimizing treatment strategies and improving patient quality of life.

Data Highlights

No numerical data available in the provided context.

Key Findings

• Chemoradiotherapy is associated with a higher incidence of SNHL compared to radiotherapy alone.
• Studies indicate that up to 82.5% of HNC patients experience SNHL following chemoradiotherapy.
• In contrast, the incidence of SNHL in patients undergoing radiotherapy alone is approximately 25.7%.
• Cisplatin-based regimens significantly contribute to the increased risk of SNHL.
• Variability in SNHL prevalence highlights the need for pooled analyses to better understand treatment impacts.

Clinical Implications

Clinicians should be aware of the heightened risk of SNHL in patients receiving chemoradiotherapy for HNC, particularly with cisplatin. Monitoring hearing function and implementing protective strategies may be essential in managing treatment-related side effects.

Conclusion

The systematic review underscores the importance of evaluating treatment modalities for HNC, as chemoradiotherapy significantly increases the risk of sensorineural hearing loss compared to radiotherapy alone.

References

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. HPV-positive OPSCC Guideline - American Society for Radiation Oncology (ASTRO)
8. Comparative analysis of prevalences of sensorineural hearing loss from chemoradiotherapy versus radiotherapy in head and neck cancer patients: a systematic review and meta-analysis - PMC